Browsing by Author "Karaca, H"

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    Acute effects of static stretching and massage on flexibility and jumping performance
    Yildiz, S; Gelen, E; Çilli, M; Karaca, H; Kayihan, G; Ozkan, A; Sayaca, C
    Objective: The purpose of this study was to evaluate the effects of static stretching and the application of massage on flexibility and jump performance. Methods: Thirty-five athletes studying Physical Education at University (mean age 23.6 +/- 1.3 years. mean height 177.8 +/- 6.3 cm and mean weight 72.2 +/- 6.7 kg) performed one of three different warmup protocols on non-consecutive days. Protocols included static stretching ISS). combined static stretching and massage [SSW, and neither stretching nor massage [CONT]. The athletes performed flexibility, countermovement jump (CMJ) and squat jump (SJ) tests. Results: SS and SSM protocols demonstrated 12%(p<0.05) and 16% (p<0.05) respectively greater flexibility than the CONT protocol. SJ and CMJ performances were significantly decreased 10.4% (p<0.05) and 5.5% (p<0.05) respectively after the SS protocol. There was no significant difference between SSM and CONT protocol in terms of SJ and CMJ performance. Conclusion: This research indicates that whereas static stretching increases the flexibility it decreases the jumping performance of the athletes. On the other hand. the application of massage immediately following static stretching increases flexibility but does not reduce jumping performance. Considering the known negative acute effects of static stretching on performance. the application of massage is thought to be beneficial in alleviating such effects.
  • No Thumbnail Available
    Item
    Frequency of EGFR Mutation in Nsclc and Its Relationship with Clinicopathological Features: A Multicenter Asmo Trial
    Yuksel, S; Kodaz, H; Yildiz, I; Odabasi, H; Ocak, A; Bayoglu, IV; Hacibekiroglu, I; Ercelep, O; Ekinci, AS; Erdogan, B; Mert, AG; Karaca, H; Salman, T; Menekse, S; Gumusay, O; Ustaalioglu, BO; Aldemir, MN; Geredeli, C; Baykara, M; Uysal, M; Sevinc, A; Aksoy, A; Ulas, A; Inanc, M; Tanriverdi, O; Avci, N; Turan, N; Aliustaoglu, M; Gumus, M
  • No Thumbnail Available
    Item
    The effect of the gastrectomy on survival in patients with metastatic gastric cancer: a study of ASMO
    Yazici, O; Özdemir, N; Duran, AO; Menekse, S; Ali, M; Sendur, N; Karaca, H; Göksel, G; Arpaci, E; Hacibekiroglu, I; Bilgetekin, I; Kaçan, T; Özkan, M; Aksoy, S; Aksoy, A; Çokmert, S; Uysal, M; Elkiran, ET; Çiçin, I; Büyükberber, S; Zengin, N
    Aim: To investigate the role of surgical resection of primary tumor on overall survival (OS) in advanced gastric cancer patients at the time of diagnosis. Patients & methods: The survival rates of metastatic gastric cancer patients whose gastric primary tumor was resected at time of diagnosis were compared with metastatic gastric cancer patients whose primary tumor was nonresected. Results: The median progression-free survival and OS in operated and nonoperated group were 10 versus 6, 14 versus 9 months, respectively (p < 0.001). In multivariate analysis, gastric resection of primary tumor, Eastern Cooperative Oncology Group performance status, second-line chemotherapy had a significant effect on OS (hazard ratio [HR]: 0.52 [95% CI: 0.38-0.71], HR: 0.57 [95% CI: 0.42-0.78], HR: 1.48 [1.09-2.01]; p <= 0.001, p = 0.001 and p = 0.012, respectively). Conclusion: Subpopulations of patients with metastatic gastric cancer might benefit from surgical removal of primary tumor.
  • No Thumbnail Available
    Item
    Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less
    Özaslan, E; Karaca, H; Koca, S; Sevinç, A; Hacioglu, B; Özkan, M; Özçelik, M; Duran, AO; Hacibekiroglu, I; Yildiz, Y; Tanriverdi, Ö; Menekse, S; Aksoy, A; Bozkurt, O; Urvay, S; Uysal, M; Demir, H; Çiltas, A; Dane, F
    The objectives of this study were to compare progression-free survival (PFS) with somatostatin analog (SSA) versus chemotherapy (CTx) in first-line therapy and to determine the patient group in which these treatments were more effective in neuroendocrine tumors (NETs) with a Ki-67 index of 20% or less. Patients who received SSA or CTx and had unresectable locally advanced and metastatic NETs with a Ki-67 index of 20% or less were retrospectively selected from 13 centers in the Turkish database between 2000 and 2015. One hundred and sixty-five patients were enrolled. The median age was 56 years and the male-to-female ratio was 1.09. Seventy-four (45%) patients were of grade 1 NET and 91 (55%) were of grade 2. SSA was given to 104 patients, whereas 61 were treated with CTx. The objective response rate after SSA was 15.4%; another 73.1% had stable disease. The objective response rate after CTx was 36.1%, and 40.9% had stable disease (P = 0.008). The median PFS in SSA patients was 21 months (95% confidence interval: 12.4-29.6), and 8 months for CTx (95% confidence interval: 5.5-10.6) (P < 0.001). There was no significant difference between PFS of receiving SSA and CTx in pancreatic neuroendocrine tumor (PNET) patients; however, the PFS of receiving SSA was longer in non-PNET patients (P < 0.001). SSA was better treatment in advanced NET patients with a Ki-67 index of less than 5%, having a primary resected and a performance status of 0 (P < 0.05). SSA may be preferred over CTx in advanced NET patients with low-to-intermediate grade. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
  • No Thumbnail Available
    Item
    The role of the gastrectomy on survival in metastatic gastric cancer patients: A multicenter study of Anatolian Society of Medical Oncology (ASMO)
    Yazici, O; Ozdemir, N; Duran, AO; Menekse, S; Sendur, MAN; Karaca, H; Goksel, G; Arpaci, E; Eren, T; Hacibekiroglu, I; Bilgetekin, I; Kacan, T; Ozkan, M; Aksoy, S; Aksoy, A; Zengin, N
  • No Thumbnail Available
    Item
    XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology
    Duran, AO; Karaca, H; Besiroglu, M; Bayoglu, IV; Menekse, S; Yapici, HS; Yazilitas, D; Bahceci, A; Uysal, M; Sevinc, A; Hacibekiroglu, I; Aksoy, A; Tanriverdi, O; Arpaci, E; Inanc, M; Dane, F; Ozkan, M
    Background: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC). The aim of this study was to compare efficacy of first-line XELOX-Bev treatment vs FOLFIRI-Bev treatment for mCRC. Materials and Methods: A total of 409 patients with mCRC who received chemotherapy were included and divided into 2 groups. Group 1 (n=298) received XELOX-Bev and Group 2 (n=111) FOLFIRI-Bev. Comparisons were made in terms of overall (OS) and progression-free (PFS) survival, response rate (RR), and grade 3-4 toxicity. Results: Median follow-up was 11 months in Group 1 and 15 months for Group 2. Complete remission was observed in 29 (9.7%) and 2 (1.8%) patients, partial remission in 139 (46.6%) and 27 (24.5%), stable disease in 88 (29.5%) and 49 (44.1%) and progressive disease in 42 (14.1%) and 33 (30.0%) patients in Group 1 and 2, respectively. Median OS was 25 months (range 2-57 months, 95% CI; 22.2-27.7) for Group 1 and 20 months (range 1-67 months, 95% CI; 16.8-23.1) for Group 2 (p=0.036). Median PFS was 9.6 months (range 2-36 months, 95% CI; 8.8-10.4) for Group 1 and 9 months (range 1-44 months, 95% CI; 7.4-10.5) for Group 2 (p=0.019). Objective RR was 56.4% in Group 1 and 26.1% in Group 2 (p<0.001). Conclusions: First-line XELOX-Bev is more effective with a better response rate, prolongation of median PFS/OS, and a superior safety profile compared with FOLFIRI-Bev.